News for Regeneron Pharmaceuticals, Inc. (REGN34.SA)

Investment firm Baird has adjusted its price target for Regeneron Pharmaceuticals (REGN), reducing it from $759 to $652 while maintaining a Neutral rating for t

Truist Securities has revised its target price for Regeneron Pharmaceuticals (REGN), reducing it from $1,004 to $975, while maintaining a Buy rating on the shar

**media[601277]**

**media[600847]**

Summary On April 18, 2025, Regeneron Pharmaceuticals Inc (REGN) announced that the U.S. Food and Drug Administration (FDA) issued a complete response letter (CR

TARRYTOWN, N.Y., April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. ( REGN) today announced that the U.S. Food and Drug Administration (FDA) h

Regeneron Pharmaceuticals (REGN) received a Complete Response Letter (CRL) from the FDA for EYLEA HD® (aflibercept) Injection 8 mg. The FDA rejected th

**media[599150]**

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than 300,000 adu

Summary: The FDA's priority review of Regeneron's Eylea HD for macular edema could be a significant catalyst, with a decision expected by August 19, 2025.

Regeneron Pharmaceuticals' (REGN) EYLEA HD® (aflibercept) Injection 8 mg has received FDA Priority Review status for a supplemental Biologics License Appl

Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs.

Guggenheim's analyst Yatin Suneja has reduced the price target for Regeneron Pharmaceuticals Inc. (REGN) from $950 to $940. Despite this adjustment, the firm ma

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc.

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other most profitable biotech stocks to buy right now. With improved market conditions, innovative breakthroughs, and more investor interest, the biotechnology industry […]

We recently published a list of 11 Blue Chip Stocks to Invest in at 52-Week Lows. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc.

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils Approval marks

**media[579109]**

**media[577816]**